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Introduction
disease. The first identified renal lesion was amyloidosis in the patients with FMF who had persistent proFamilial Mediterranean fever ( FMF ) is an autosomal teinuria [4] . In 1955, Shwayri and Tutunji [8] reported recessive hereditary disease which primarily affects a case whereby a patient had abdominal and thoracic Jews, Armenians, Arabs and Turks [1, 2] . The disease pain ( FMF ) with synchronous gross haematuria, but was first outlined by Siegal in 1945 and characterized no tissue diagnosis was available. Furthermore, the by recurrent and self-limited attacks of fever, usually occurrence of microscopic haematuria during attacks, accompanied by peritonitis, pleuritis, arthritis or erybut sometimes also in no relation to them, has been sipelas-like erythaema [3] . The development of amyl-observed [5] . In 1970, Eliakim et al. analysed renal oidosis is the most common renal complication of manifestations of 106 patients with FMF and found FMF that leads inevitably to chronic renal failure that 12.3% had amyloidosis, while 21.7% had renal [4] [5] [6] [7] . The frequency of amyloidosis differs among lesions other than amyloidosis. Patients in the last various ethnic groups and depends on whether patients category clinically presented with transient or persistent are taking colchicine [1, 2] . It has been well documented haematuria and albuminuria, particularly during that the presence of amyloidosis determines the pro-attacks, and a variety of glomerulonephritides includgnosis of the disease. However, in addition to amyl-ing acute post-streptococcal glomerulonephritis and oidosis other renal lesions have been described in the Henoch-Schö nlein purpura (HSP) were found. patients with FMF and it seems that these renal lesions Histologically some of the kidney biopsies showed have been relatively neglected [6] [7] [8] [9] [10] [11] [12] [13] . mesangial proliferation, but no immunoflourescence studies were performed [7] . In 1982, Flatau et al. showed focal mesangial proliferative glomerulo-
The spectrum of renal involvement other than nephritis in two patients who had FMF and HSP [13] .
amyloidosis in FMF
During the last decade more renal biopsies were performed in patients with FMF who had urinary findings. Soon after the first well documented cases of FMF A variety of non-amyloid glomerular diseases were were published it became apparent that renal involve-described. The presence of mesangial proliferation, IgM nephropathy, IgA nephropathy, focal and diffuse glomerulonephritis, and rapidly progressive glomerulo-the glomerulus and facilitates the development of these non-amyloid glomerular diseases. nephritis were reported in patients with FMF even in the absence of amyloidosis [6, [9] [10] [11] [12] . In addition, some of the non-amyloid glomerular lesions described in the Conclusion patients with FMF were associated with vasculitis [6, 7, [12] [13] [14] . Furthermore, the coexistence of a variety
The observations reported from different countries of vasculitic syndromes with FMF was noted to be indicate that the patients with FMF are prone to more frequent than in general population [13, 14] . exhibit a variety of glomerular diseases other than amyloidosis. Although amyloid renal disease is definitely common in FMF patients, there are no good
Possible pathogenesis
epidemiological studies showing that non-amyloid glomerular diseases are also more frequent in the The biochemical basis of FMF is still unknown but patients with FMF than in the general population. An the gene responsible for the disease was cloned recently important source of confusion is the interpretation of by two independent teams [15, 16 ] . The gene product persistent albuminuria as a sign of amyloidosis in the called pyrin/marenostrin was reported to be a protein absence of histologic proof. It is pertinent to point out that is responsible for limiting the intensity of inflamthat the actual frequency of non-amyloid glomerular mation. It was suggested that FMF-associated mutalesions in patients with FMF depends largely on the tions and the resultant structural changes of the protein number of kidney biopsies performed in patients with interfere with the normal pyrin/marenostrin mediabnormal urinary findings. ated negative feed back mechanism, thus favouring
Colchicine treatment was clearly shown to ameliorthe onset and persistence of inflammation [15] [16] [17] .
ate the course of FMF and to prevent the development Although the identification of the FMF gene advanced of amyloidosis [1, 2] . A review of the literature reveals the understanding of the regulation of acute inflamthat some of the FMF patients were not taking regular matory responses, the pathogenesis of the disease is colchicine treatment when they developed non-amyloid still obscure. Based on clinical and laboratory findings glomerular diseases [5] [6] [7] [8] [9] [10] [11] [12] . It remains to be seen several pathogenetic mechanisms have been suggested.
whether regular colchicine treatment that prevents Circulating immune complexes, complement consumpacute attacks and amyloidosis, may prevent the develtion, increased concentrations of immunoglobulins opment of non-amyloid glomerular diseases in the during attacks and return to normal after the acute patients with FMF. Finally, it is important to emphasattacks support the notion that an immune reactant ize that non-amyloid glomerular diseases should be mechanism underlies FMF [6 ] . The results of three multicentre trials made in Italy ated with a nephrotic syndrome. The renal prognosis showed the effectiveness of a schedule based on alternmay be variable but a recent review of the available ating cycles of methylprednisolone and chlorambucil studies, including nephrotic and non-nephrotic every other month for 6 months. A first study compatients, reported that renal survival at 10 years was pared the effects of methylprednisolone and chloram-0.65 [1] . It is likely, however, that the prognosis is bucil and those of symptomatic treatment in patients even worse in nephrotic patients, as the risk of renal with IMN and nephrotic syndrome. At 10 years, 92% failure is correlated to the severity and the duration of of treated patients versus 60% of untreated controls proteinuria [2] . Nephrotic patients are also exposed to were still alive without dialysis. Treated patients spent an increased risk of cardiovascular death [3] as well 58% of their time without nephrotic syndrome versus as to intravascular thrombosis and other potential 22% of controls [5] . A second study compared methylcomplications [4] . Thus, although many clinicians still prednisolone and chlorambucil, and methylprednisoadhere to the dogma that IMN should not be treated, lone alone given at the same cumulative dose. At the it is our opinion that any treatment that is able to end of a mean follow-up of 54 months, 64% of patients modify the natural course of this disease in patients given methylprednisolone and chlorambucil versus with the nephrotic syndrome is welcome.
38% of patients given methylprednisolone alone were without nephrotic syndrome, the difference being significant [6 ] . In a third trial methylprednisolone and Treatment with corticosteroids and/or cytotoxic chlorambucil were compared with methylprednisolone agents alternated with cyclophosphamide [7] . The probability of attaining as a first event complete or partial remisCorticosteroids have been used in IMG for many sion of the nephrotic syndrome was similar (82 vs years. A meta-analysis of the available controlled trials 93%), the risk of relapse was also similar (30 vs 20%). concluded that, at least at the doses used in the few Thus, the use of steroids alternated with either chloravailable randomized trials, corticosteroids neither ambucil or cyclophosphamide may favour remission improve the probability of remission of proteinuria of the nephrotic syndrome and may protect renal nor protect from renal function deterioration [1] . function in the long term. It is worth rememberControlled studies showed that the administration of ing that in more than half of responders, remission cyclophosphamide or chlorambucil for 1 year or more of proteinuria develops weeks or months after the may cause consistent reduction of proteinuria in a treatment was completed [5] [6] [7] .
Results with cyclosporin
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